PAVMED INC (PAVM)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$5.28+3.73%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · PAVM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 747.5% |
| Our one-year growth estimate | diamond | -55.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 803.1 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
PAVM — earnings miss
Dated 2026-05-15
is incorporated herein by reference. The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Why it matters: Managing cash burn is key for survival. Improvement may show better financial health.
Supportive ifOperating losses drop a lot. This shows better cash flow management.
Worry ifOperating losses worsen or cash burn remains high.
Why it matters: Managing cash burn is key for survival. Improvements show better financial health.
Worry ifManagement says operating losses fell to less than -$4M.
Less concerning ifOperating losses increase beyond -$8M in Q2.
Why it matters: Getting money is key to keep things running while spending cash.
Supportive ifAnnouncement of a new financing round or capital raise.
Worry ifNo updates or bad news about capital raising efforts.
Why it matters: The FDA submission is a key step for Veris Health's growth and market entry.
Supportive ifVeris Health will finish its FDA 510(k) submission for the monitor by early 2027.
Worry ifThe FDA submission is delayed beyond early 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$340 on $10,000 · ±3.4% | How much price usually moves either way. |
| Bad day | $880 loss on $10,000 · 8.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,473 loss on $10,000 · 74.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: EsoGuard's growing revenue shows it is accepted in the market and getting paid for.
Supportive ifEsoGuard revenue increases by more than 10% from Q2 2026 to Q3 2026.
Worry ifEsoGuard revenue declines or grows less than 10% from Q2 2026 to Q3 2026.
Why it matters: High cash burn limits how the company can operate and may affect future funding.
Worry ifOperating cash burn remains above $2.6 million in Q3 2026.
Less concerning ifOperating cash burn decreases below $2.6 million in Q3 2026.
Why it matters: Improving the PortIO device is key for PAVmed's medical device line and growth.
Supportive ifPAVmed completes the FDA pre-submission process for PortIO by Q4 2026.
Worry ifThe FDA pre-submission process for PortIO is delayed beyond Q4 2026.